The most common typically strongest in the first 48 weeks as the body adapts include: Nausea (most common, usually dose-dependent) Diarrhoea or constipation Fatigue , especially during dose escalations Mild headache Reflux and acid reflux Loss of appetite (this is the therapeutic effect, not a side effect, but it can be uncomfortable) Less common but more serious effects warranting immediate physician review include pancreatitis, gallbladder disease, and kidney issues, particularly in patients with pre-existing conditions
In comparison, participants in the placebo group experienced a reduction of 0.81%
GIP receptor (GIPR) is also a type B G-protein-coupled receptor, which exists in various tissues such as pancreas, adipose tissue, gastric mucosa, heart, adrenal cortex, bone and brain
Bottom Line BPC-157 has compelling animal data and a plausible biological mechanism
Psychological and quality of life changes in patients using GLP-1 analogues